Carlsmed, Inc. CARL
15.10
0.28
1.89%
as of 25 Sep
- Market cap
- $404.6M
- P/E
- 0.0×
Follow CARL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+5 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.73 | 3.48 | 4.30 | 4.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.37) | (33.01) | (18.67) | (38.36) | |
P/B ratio |
2.65 | 1.78 | 2.63 | 3.35 | |
Price to Tangible BV |
2.65 | 1.78 | 2.63 | 3.35 | |
EV/Sales |
4.35 | 1.61 | 2.85 | 3.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.54) | (2.80) | (4.76) | (6.10) | |
EV/FCF |
(6.27) | (2.67) | (4.58) | (5.84) | |
Quick Ratio |
11.60 | 8.49 | 11.26 | 8.32 | |
Current Ratio |
12.03 | 8.87 | 11.88 | 8.84 | |
Net Debt/EBITDA |
11.17 | 10.25 | 8.91 | 6.78 | |
Debt/Assets |
11.45% | 11.79% | 12.94% | 13.01% | |
Debt/Equity |
0.14 | 0.16 | 0.17 | 0.18 | |
Asset Turnover |
0.45 | 0.78 | 0.95 | 0.74 | |
Operating CF/Net income |
0.99 | 0.62 | 1.50 | 0.70 | |
Capex/Depreciation |
(4.18) | (2.35) | (2.08) | (5.76) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
34.00% | 34.71% | 32.13% | 31.89% | |
Selling, General and Administrative Expense of Revenue |
111.04% | 103.28% | 102.53% | 103.16% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.38% | 5.21% | 10.11% | 11.99% | |
Graham Net Nets |
0.37 | 0.54 | 0.37 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(39.21%) | (29.64%) | (27.73%) | (13.78%) | |
Free Cash Flow Yield |
(10.29%) | (17.27%) | (14.47%) | (12.64%) | |
Revenue per Share |
0.62 | 1.07 | 0.60 | 0.70 | |
Operating CF per Share |
(0.40) | (0.37) | (0.48) | (0.27) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.03) | |
Free Cash Flow per Share |
(0.42) | (0.39) | (0.49) | (0.30) | |
Cash per Share |
5.48 | 7.73 | 3.62 | 3.29 | |
Shareholders Equity per Share |
5.06 | 6.95 | 3.44 | 3.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.06 | 6.95 | 3.44 | 3.10 | |
Free Cash Flow |
(8.80) | (5.55) | (13.21) | (8.11) | |
Working Capital |
120.54 | 112.39 | 105.69 | 97.20 | |
Capital Expenditures |
(0.34) | (0.23) | (0.21) | (0.75) | |
Net Current Asset Value |
103.26 | 95.42 | 88.89 | 75.64 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.04 | |
Net Profit Margin |
(65.21%) | (56.80%) | (53.96%) | (55.49%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 9.06 | 9.52 | 11.74 | |
Average Payables |
— | 3.45 | 2.68 | 3.14 | |
Average Inventory |
— | 1.42 | 1.53 | 1.67 | |
Average Assets |
93.34 | 65.06 | 59.38 | 85.74 | |
Average Common Equity |
— | 14.12 | 10.81 | 0.59 |
Columns are period end dates